Wiggin and Dana Represents IsoPlexis in Series C Financing

May 15, 2019 Press Release

Wiggin and Dana client IsoPlexis, a biotechnology company focused on advancing single-cell biomarkers to address critical challenges in oncology & beyond, recently announced that it has secured $25 million in Series C funding from several investors including Northpond Ventures, Spring Mountain Capital, Ironwood Capital, North Sound Capital, and Connecticut Innovations.

For more information about this transaction, please click here.